share_log

GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

GeoVax 將於 2023 年 11 月 8 日公佈 2023 年第三季度財務業績並提供公司最新情況
GlobeNewswire ·  2023/10/31 21:00

GeoVax to Host Conference Call at 4:30 PM ET

GeoVax 將於美國東部時間下午 4:30 主持電話會議

ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.

喬治亞州亞特蘭大,2023年10月31日(GLOBE NEWSWIRE)——通過NewMediaWire——開發免疫療法和癌症和傳染病疫苗的臨床階段生物技術公司GeoVax Labs, Inc.(納斯達克股票代碼:GOVX)今天宣佈,將在美國市場收盤後於2023年11月8日星期三公佈2023年第三季度財務業績。發佈後,管理層將在美國東部時間下午 4:30 主持電話會議和網絡直播,包括問答,以提供公司最新情況並討論財務業績。

Dial-in numbers:
Domestic: 800-715-9871
International: 646-307-1963
Conference ID: 7519986

撥入號碼:
國內:800-715-9871
國際:646-307-1963
會議編號:7519986

Webcast:
A webcast of the live call may be accessed here and on the Events page of the GeoVax website.
A webcast replay of the call will be available for three months via the same link as the live webcast approximately two hours after the end of the call.

網絡直播:
可以在此處和GeoVax網站的活動頁面上觀看實時電話會議的網絡直播。
電話會議結束大約兩個小時後,將通過與網絡直播相同的鏈接進行爲期三個月的網絡直播重播。

About GeoVax

關於 GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world's most threatening infectious diseases. The company's lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax's lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: .

GeoVax Labs, Inc. 是一家處於臨床階段的生物技術公司,爲實體瘤癌和許多世界上最具威脅性的傳染病開發新療法和疫苗。該公司在腫瘤學領域的領先項目是一種新型的溶瘤實體瘤基因定向療法 Gedeptin,目前正在進行一項針對晚期頭頸癌的多中心 1/2 期臨床試驗。GeoVax 的主要候選傳染病是 GEO-CM04S1,這是一種針對高風險免疫功能低下患者群體的下一代 COVID-19 疫苗。目前正在三項二期臨床試驗中,GEO-CM04S1 被評估爲免疫功能低下的患者(例如血液系統癌症患者和其他目前授權的 COVID-19 疫苗不足的患者群體)的初級疫苗,以及慢性淋巴細胞白血病(CLL)患者的加強疫苗。此外,GEO-CM04S1 正在進行二期臨床試驗,評估該疫苗在先前接種過 mRNA 疫苗的健康患者中是一種更強大、更耐用的 COVID-19 增強劑。GeoVax擁有一支領導團隊,在過去的幾十年中,他們推動了多家生命科學公司的重大價值創造。想要查詢更多的信息, 訪問我們的網站:.

Company Contact: Investor Relations Contact: Media Contact:
info@geovax.com paige.kelly@sternir.com sr@roberts-communications.com
678-384-7220 212-698-8699 202-779-0929
公司聯繫人: 投資者關係聯繫人: 媒體聯繫人:
info@geovax.com paige.kelly@sternir.com sr@roberts-communications.com
678-384-7220 212-698-8699 202-779-0929

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論